Transfusion‐related adverse events in the Platelet Dose study. Issue 1 (28th July 2014)

• Record Type: Journal Article
• Authors: Kaufman, Richard M.; Assmann, Susan F.; Triulzi, Darrell J.; Strauss, Ronald G.; Ness, Paul; Granger, Suzanne; Slichter, Sherrill J.
• Is Part Of: Transfusion. Volume 55:Issue 1(2015)
• Page Start: 144
• Page End: 153
• Publication Date: 2014-07-28
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.12791
• Languages: English
• ISSNs: 0041-1132

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="trf12791-sec-0001" sec-type="section"> <title>Background</title> <p>How platelet (PLT) product characteristics such as dose, source (whole blood derived [WBD] vs. apheresis), storage duration, and ABO matching status affect the risks of transfusion‐related adverse events (TRAEs) is unclear. Similarly, more information is needed to define how recipient characteristics affect the frequency of TRAEs after PLT transfusion.</p> </sec> <sec id="trf12791-sec-0002" sec-type="section"> <title>Study Design and Methods</title> <p>In the multicenter Platelet Dose ("PLADO") study, pediatric and adult hematology‐oncology patients with hypoproliferative thrombocytopenia were randomized to receive low‐dose (LD), medium‐dose (MD), or high‐dose (HD) PLT prophylaxis for a pretransfusion PLT count of not more than 10 × 10<sup>9</sup>/L. All PLT units (apheresis or WBD) were leukoreduced. Post hoc analyses of PLADO data were performed using multipredictor models.</p> </sec> <sec id="trf12791-sec-0003" sec-type="section"> <title>Results</title> <p>A total of 5034 PLT transfusions to 1102 patients were analyzed. A TRAE occurred with 501 PLT transfusions (10.0%). The most common TRAEs were fever (6.6% of transfusions), allergic or hypersensitivity reactions (1.9%), and sinus tachycardia (1.8%). Patients assigned HD PLTs were more likely than LD or MD patients to experience any TRAE (odds ratio for HD vs. MD, 1.50; 95% confidence interval, 1.10‐2.05; three‐group comparison p = 0.02). PLT source and ABO matching status were not significantly related to overall TRAE risk. Compared to a patient's first PLT transfusion, subsequent PLT transfusions were less likely to have a TRAE reported, primarily due to a lower risk of allergic or hypersensitivity reactions.</p> </sec> <sec id="trf12791-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The most important PLT unit characteristic associated with TRAEs was PLT dose per transfusion. HD PLTs may increase the risk of TRAEs, and LD PLTs may reduce the risk.</p> </sec> </abstract>